In fact, a phase I trial combining MLN0128 (sapanisertib), an mTOR inhibitor, and CB-839, a glutaminolysis inhibitor, is ongoing in patients with advanced NSCLC (KRAS-mutant LUAD and LUSC) having NFE2L2/KEAP1 mutations [234]. Here, NFE2L2 is linked to non-small cell lung carcinoma.